Back to search results

Genetic Studies of Early-onset Dementia

This study is looking for people aged 35 and older who are experiencing memory concerns or have been diagnosed with dementia, as well as healthy family members without dementia. The goal is to understand the genetic factors that contribute to early-onset dementia (memory loss before age 70), including Alzheimer's Disease and mild cognitive impairment (MCI). Participants will have a blood draw to look for genetic changes, take a brief memory test (neurocognitive testing), and complete a medical questionnaire. The researchers hope to identify genetic risk factors and changes in blood markers related to early-onset dementia within two years. The study is currently recruiting participants.

Study design
This is an observational study aiming to enroll 1000 participants. It is not a treatment study, but rather looks at genetic factors.
What's involved
You would have a blood draw, a brief memory test, and complete a medical questionnaire.
Compensation
Not stated in the trial record.
Follow-up
The study will measure genetic risk variants and changes in blood biomarkers over two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04906863

Genetic Studies of Early-onset Dementia

Recruiting
Not specifiedAges 35+Observational
Columbia University
~1,000 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Blood drawNeurocognitive testingMedical questionnaire

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Genetic risk variants associated with early-onset dementia
Measured over 2 years
+1 more outcome measured

Conditions

Dementia, Early Onset
Alzheimer Dementia (AD)
Mild Cognitive Impairment (MCI)
Memory Loss

Explore related trials

Alzheimer's DiseaseDementiaMild cognitive disorder

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Christiane Reitz, MD, PhD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Pamela Del Rosario
[email protected]
212-304-7284
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

35 years and older
Individuals experiencing memory concerns or diagnosed with dementia and their family members that are unrelated healthy controls without dementia.

What this trial measures

  • Genetic risk variants associated with early-onset dementia2 years

    Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.

  • Changes in blood biomarkers in early-onset dementia2 years

    Blood biomarkers including plasma amyloid beta and tau protein will be assessed in blood and correlated with onset and progression of memory loss and functional impairment